Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis
The pathophysiology of multiple sclerosis involves an autoimmune and a neurodegenerative mechanism. Central nervous system-infiltrating immune cells in multiple sclerosis also possess a neuroprotective activity through secretion of neurotrophins, such as brain-derived neurotrophic factor. Fingolimod was shown to slow the progression of disability and loss of brain volume.
The objective of this study was to explore whether fingolimod induces secretion of neurotrophins by immune cells.
Blood was drawn from 21 patients before the initiation of treatment with fingolimod and at 6 and 12 months of follow-up. The levels of the neurotrophic factors brain-derived neurotrophic factor, glial cell-derived neurotrophic factor, β-nerve growth factor, neurotrophin-3, neurotrophin-4, basic fibroblast growth factor, epidermal growth factor, and vascular endothelial growth factor were screened in the supernatants of separated T cells and monocyte cultures using a customized, multiplex enzyme-linked immunosorbent assay. Brain-derived neurotrophic factor levels were further validated by a specific enzyme-linked immunosorbent assay.
Treatment with fingolimod significantly increased brain-derived neurotrophic factor secretion from T cells. A specific enzyme-linked immunosorbent assay confirmed these results in the supernatant of T cells after 6 and 12 months of therapy.
T cells that reach the bloodstream of fingolimod-treated patients with multiple sclerosis may contribute to the neuroprotective effect of this therapy by increased secretion of brain-derived neurotrophic factor. This mechanism of action of fingolimod in patients with multiple sclerosis has not been previously reported.
We thank Esther Eshkol, institutional medical copy editor of Tel Aviv Sourasky Medical Center, for assistance in drafting the manuscript.
Compliance with Ethical Standards
Novartis AG partially supported the study.
Conflict of interest
Maya Golan, Karin Mausner-Fainberg, Bassima Ibrahim, Moshe Benhamou, Adi Wilf-Yarkoni, Hadar Kolb, Keren Regev, and Arnon Karni have no conflicts of interest that are directly relevant to the content of this study.
The study was approved by the local institutional review board in Helsinki (Research No. 0584-13-TLV).
Consent to Participate
All the participants in the study signed an informed consent form upon enrollment.
- 2.Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases. Brain. 1999;122(Pt 12):2279–95.Google Scholar
- 5.De Santi L, Polimeni G, Cuzzocrea S, Esposito E, Sessa E, Annunziata P, et al. Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment. Curr Med Chem. 2011;18:1775–84.Google Scholar
- 11.Peckham H, Giuffrida L, Wood R, Gonsalvez D, Ferner A, Kilpatrick TJ, et al. Fyn is an intermediate kinase that BDNF utilizes to promote oligodendrocyte myelination. Glia. 2016;64:255–69.Google Scholar
- 13.Hofer MM, Barde YA. Brain-derived neurotrophic factor prevents neuronal death in vivo. Nature. 1988;331:261–2.Google Scholar
- 16.Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med. 1999;189:865–70.PubMedPubMedCentralGoogle Scholar
- 17.Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011;14:347–53.Google Scholar
- 18.Azoulay D, Urshansky N, Karni A. Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. J Neuroimmunol. 2008;195:186–93.Google Scholar
- 21.Urshansky N, Mausner-Fainberg K, Auriel E, Regev K, Farhum F, Karni A. Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis. J Neurol Sci. 2010;295:31–7.Google Scholar
- 22.Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883–97.Google Scholar
- 23.Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung H-P. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol. 2012;142:15–24.Google Scholar
- 25.Matsumoto N, Hirose R, Sasaki S, Fujita T. Synthesis of the key intermediate, diethyl 2-acetylamino-2-(2-(4-octanoylphenyl)ethyl)propane-1,3-dioate, of the immunomodulatory agent FTY720 (fingolimod). Chem Pharm Bull (Tokyo). 2008;56:595–7.Google Scholar
- 26.Balatoni B, Storch MK, Swoboda E-M, Schonborn V, Koziel A, Lambrou GN, et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull. 2007;74:307–16.Google Scholar
- 29.Noda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol. 2013;256:13–8.Google Scholar
- 30.Barkhof F, de Jong R, Sfikas N, de Vera A, Francis G, Cohen J. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl. Mult Scler. 2014;20:1704–13.Google Scholar
- 44.Lewin GR, Barde YA. Physiology of the neurotrophins. Annu Rev Neurosci. 1996;19:289–317.Google Scholar